姓    名：潘晓彦

职称职务：副研究员

电子邮箱：panxy@wh.iov.cn

研究方向

1.高致病性病原的进入机制机理研究；

2.基于病毒囊膜蛋白发现候选药物和疫苗；

教育及工作经历

2011.9-2016.6于南方医科大学药理学专业攻读医学博士学位

2016.8-2018.8于中国科学院武汉病毒研究所从事博士后研究工作

2018.8-2020.9中国科学院武汉病毒研究所 任助理研究员

2020.9-至今中国科学院武汉病毒研究所 任副研究员

2022.9-至今 中国科学院武汉病毒研究所 任青年研究员

近五年承担项目

1.作为课题负责人参与一项中科院STS项目，270万元；

2.作为课题负责人参与一项国家自然科学基金重点项目，获经费支持72.5万元；

3.入选中国科学院“青年创新促进会会员”，获经费支持80万元；

4.主持一项武汉市知识创新专项，获经费支持20万元；

5.主持一项国家自然科学基金青年基金，28.8万元（已结题）；

6.主持新冠病毒疫苗研制项目，共获约500万元经费支持。

近五年代表性论文

1.Li H(#), Cheng C(#), Shi S(#), Wu Y, Gao Y, Liu Z, Liu M, Li Z, Huo L, Pan X*, Liu S*, Song G*. Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein. Eur J Med Chem. 2022;238:114426.

2.Pan X(#), Shi J(#), Hu X(#), Wu Y, Zeng L, Yao Y, Shang W, Liu K, Gao G, Guo W, Peng Y, Chen S, Gao X, Peng C, Rao J, Zhao J, Gong C, Zhou H, Lu Y, Wang Z, Hu X, Cong W, Fang L, Yan Y, Zhang J, Xiong H, Yi J, Yuan Z*, Zhou P*, Shan C*, Xiao G*. RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. Cell Discov. 2021;7(1):82.

3.Bingqing Xia(#), Xurui Shen(#), Yang He(#), Xiaoyan Pan(#), Feng-Liang Liu(#), Yi Wang, Feipu Yang, Sui Fang, Yan Wu, Zilei Duan, Xiaoli Zuo, Zhuqing Xie, Xiangrui Jiang, Ling Xu , Hao Chi, Shuangqu Li, Qian Meng, Hu Zhou, Yubo Zhou, Xi Cheng Xiaoming Xin, Lin Jin, Hai-Lin Zhang, Dan-Dan Yu, Ming-Hua Li, Xiao-Li Feng, Jiekai Chen, Hualiang Jiang, Gengfu Xiao, Yong-Tang Zheng*, Lei-Ke Zhang*, Jingshan Shen*, Jia Li*, Zhaobing Gao*. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damage and constitutes an antiviral target. Cell Res. 2021; 31(8):847-860.

4.Jing Wu(#), Yuheng Shi(#), Xiaoyan Pan(#), Shuang Wu, Ruixia Hou, Yong Zhang, Tiansheng Zhong, Hao Tang, Wei Du, Luying Wang, Jing Wo, JingFang Mu, Yang Qiu, Ke Yang, Lei-Ke Zhang*, Bang-Ce Ye*, Nan Qi*. SARS-CoV-2 ORF9b Inhibits RIG-I-MAVS Antiviral Signaling by Interrupting K63-Linked Ubiquitination of NEMO. Cell Rep. 2021; 34(7):108761.

5.   Yang C(#), Pan XY(#), Xu XF, Chen C, Huang Y, Li L, Jiang SB, Xu W*, Xiao GF*, Liu SW*. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-1 helix bundle core of spike protein. Signal Transduct Target Ther. 2020; 5:220.

6.   Pan XY(#), Zhou PF, Fan TJ, Wu Y, Zhang J, Shi XY, Shang WJ, Fang LJ, Jiang XM, Shi J, Sun Y, Zhao SJ, Gong R, Chen Z*, Xiao GF*. Immunoglobulin fragment F(ab') 2 against RBD potently neutralizes SARS-CoV-2 in vitro. Antiviral Res. 2020; 10:104868.

7.   Pan XY(#), Wu Y, Wang W, Zhang LK, Xiao GF*. Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus. Antiviral Res. 2020; 174:104666.

8.   Pan XY(#), Wu Y, Wang W, Zhang LK, Xiao GF*. Novel neutralizing monoclonal antibodies against Junin virus. Antiviral Res. 2018; 156：21-28.

9.   Pan XY(#), Lin J(#), Zeng XY, Li WJ, Wu WJ, Wan ZL, Liu J, Liu SW*. Heat shock factor 1 suppresses the HIV-induced inflammatory response by inhibiting nuclear factor-κB. Cell Immunol. 2018；327：26-35.

10. Pan XY（#）, Zhao W, Wang CY, Lin J, Zeng XY, Ren RX, Wang K, Xun TR, Shai Y*, Liu SW*. Heat shock protein 90 facilitates latent HIV reactivation through maintaining the function of positive transcriptional elongation factor b (p-TEFb) under proteasome inhibition. J Biol Chem. 2016; 291(50): 26177-26187.